CA4PCombretastatin A-4 Phosphate
Copyright 1988-2018, All rights reserved.
References in periodicals archive ?
Therefore, we intend to construct a SPECT imaging probe based on H33258 and explore its potential for early prediction of tumor response to VDAs treatment with CA4P as a representative.
Finally, its potential for early prediction of tumor response to CA4P treatment was explored in W256 tumor-bearing rats.
United States-based Mateon Therapeutics has revealed encouraging data from its first interim scheduled analysis of the ongoing phase 2/3 trial of its drug, CA4P, in platinum resistant ovarian cancer patients, it was reported yesterday.
No significant safety issues were identified in the interim analysis, and the overall safety profile of CA4P was similar to or better than results seen in earlier randomised trials of CA4P.
Lu et al., "Thyroidectomy followed by fosbretabulin (CA4P) combination regimen appears to suggest improvement in patient survival in anaplastic thyroid cancer," Surgery, vol.
The data were presented at the 2012 American Association of Endocrine Surgeons Meeting in Iowa City, in an oral presentation titled, "Thyroidectomy Followed by Fosbretabulin (CA4P) Combination Regimen Appears to Suggest Improvement in Patient Survival in Anaplastic Thyroid Cancer," by Julie A.
Biopharmaceutical company OXiGENE (NasdaqCM:OXGN) disclosed on Friday the receipt of the European Commission's orphan drug designation for CA4P for the treatment of gastro-entero-pancreatic neuroendocrine tumors (NETs).
Combretastatin A-4 Phosphate (CA4P) is a novel anti-cancer agent that has displayed potent and selective toxicity towards tumor vasculature in clinical studies to date.
As part of the analysis, patients were given the combination of ZYBRESTAT (fosbretabulin tromethamine or CA4P) and Avastin (bevacizumab) and evaluated the toxicity.
4 November 2011 - OXiGENE Inc (NASDAQ:OXGN), the US-based biopharmaceutical company developing cancer and eye diseases treatments, unveiled on Thursday the final results of its FALCON Phase II trial of ZYBRESTAT (fosbretabulin tromethamine, or CA4P) in patients with advanced non-small cell lung cancer (NSCLC).
The company said that it has achieved encouraging results from the FACT Study, a randomised, controlled, Phase 2/3 study of ZYBRESTAT (fosbretabulin, CA4P) in patients with anaplastic thyroid cancer (ATC).
19 November 2010 - US-based biopharmaceutical company OXiGENE Inc (NASDAQ: OXGN) announced today it has presented updated safety and clinical activity data from the FALCON trial, a randomised, controlled Phase II study of ZYBRESTAT (CA4P) in patients with non-small cell lung cancer (NSCLC).